These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23996383)

  • 1. Reply to: letter to the editor "subcutaneous herceptin therapy".
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Dec; 53(12):1343-4. PubMed ID: 23996383
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous herceptin therapy.
    O'Donoghue N; Quintyne KI; Woulfe B; Gupta R; O'Reilly S
    J Clin Pharmacol; 2013 Dec; 53(12):1341-2. PubMed ID: 23996323
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous trastuzumab (Herceptin) injection shows promise.
    Oncology (Williston Park); 2012 Sep; 26(9):873. PubMed ID: 23061348
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].
    Lieutenant V; Toulza É; Pommier M; Lortal-Canguilhem B
    Bull Cancer; 2015 Mar; 102(3):270-6. PubMed ID: 25725921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. As treatment options progress, so must we.
    Harmer V
    Br J Nurs; 2013 May 23-Jun 12; 22(10):S3. PubMed ID: 23752364
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to the letter to the editor 'patients' preference and informed consent' by Pumo et al.
    Pivot X; Machackova Z
    Ann Oncol; 2015 Jun; 26(6):1269-1270. PubMed ID: 25787922
    [No Abstract]   [Full Text] [Related]  

  • 8. [New hypodermic syringe improves administration quality].
    Kreutzkamp B
    Med Monatsschr Pharm; 2015 May; 38(5):195-6. PubMed ID: 26364411
    [No Abstract]   [Full Text] [Related]  

  • 9. Can NOAH guide us to improved survival in breast cancer?
    Johnston SR
    Lancet Oncol; 2014 May; 15(6):550-2. PubMed ID: 24657002
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there an ideal way to combine trastuzumab with chemotherapy?
    Gonzalez-Angulo AM; Hortobagyi GN
    J Clin Oncol; 2011 Dec; 29(34):4474-6. PubMed ID: 22042935
    [No Abstract]   [Full Text] [Related]  

  • 11. Duration of adjuvant trastuzumab: shorter beats longer.
    Joensuu H
    Lancet; 2013 Sep; 382(9897):1010-1. PubMed ID: 23871493
    [No Abstract]   [Full Text] [Related]  

  • 12. PrefHer: finally addressing the preferences of her, too.
    Melichar B
    Lancet Oncol; 2013 Sep; 14(10):914-5. PubMed ID: 23965224
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current studies reveal significant survival advantage. Breast cancer therapy with herceptin].
    Krankenpfl J; 2003; 41(10-12):215. PubMed ID: 14746196
    [No Abstract]   [Full Text] [Related]  

  • 14. The hype over herceptin.
    Fitzpatrick J
    Nurs N Z; 2009 Mar; 15(2):4-5. PubMed ID: 19554708
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combination therapy herceptin+taxotere/Herceptin+navelbine].
    Meden H
    Onkologie; 2002 Dec; 25 Suppl 5():15-6. PubMed ID: 23573614
    [No Abstract]   [Full Text] [Related]  

  • 16. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies: HERA update-1 year is standard.
    Hutchinson L
    Nat Rev Clin Oncol; 2013 Oct; 10(10):546. PubMed ID: 23917526
    [No Abstract]   [Full Text] [Related]  

  • 18. Desensitization to chemotherapeutic agents.
    Lieberman P; Castells M
    J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast cancer drug warning.
    Johns Hopkins Med Lett Health After 50; 2012 Dec; 24(11):8. PubMed ID: 23342677
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose scheduling--Herceptin.
    Leyland-Jones B
    Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.